WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for ...

γ-herpesvirus genomes encode an abundance of homologues of cellular factors, including cyclin and Bcl-2. These viral homologues differ from their cellular counterparts in that the viral proteins ...

Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) is expected to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Cyclacel Pharmaceuticals to ...

StockNews.com started coverage on shares of MEI Pharma (NASDAQ:MEIP – Free Report) in a report issued on Saturday morning. The firm issued a buy rating on the stock. MEI Pharma Price Performance MEIP ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Beigene Switzerland GmbH has divulged CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Single-cell analysis revealed the molecular triggers that drive stem cells to become cancerous, which may help inform ...